Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults
about
Using an Adenosine Triphosphate Bioluminescent Assay to Determine Effective Antibiotic Combinations against Carbapenem-Resistant Gram Negative Bacteria within 24 HoursEffective antibiotics in combination against extreme drug-resistant Pseudomonas aeruginosa with decreased susceptibility to polymyxin BFrom Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic reviewIn vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis PatientsPharmacokinetics and pharmacodynamics of antibacterial agents.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.Quantitative assessment of combination antimicrobial therapy against multidrug-resistant Acinetobacter baumannii.Amikacin Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis in Pediatric Cancer Patients.High-dose amikacin for achieving serum target levels in critically ill elderly patients.Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis
P2860
Q28391044-6CB32013-A2E8-44B3-B77E-8F5B9328F63BQ28478261-DC769656-AE21-450C-B389-332CD67735E8Q28552767-3DCA7817-ED5C-4998-8BA6-EE8B572AC97EQ35089403-D5A5A7CC-2C3C-4008-805E-8BF3762E7CAFQ35385713-5DEF1301-1FC2-4F46-B74E-E13B457D69B1Q36075986-22A27FD3-E984-49F6-A564-55D16160A436Q36911111-2B4BCD4D-AC5C-4E23-9487-2B13B4914001Q37203872-15AB3EFB-F44A-4CF1-8103-6F0215E40E6FQ37538693-51DC5CA3-5045-49E3-80CB-34B85C307A40Q37653435-6951C310-EA98-4D70-BE92-D993D316761DQ38895149-0D36D946-974B-4B4E-910F-10E637BC390EQ41338910-A4646CF5-FE44-4F72-83E5-356E457F1444Q48528055-41CD9030-FD41-4F5C-A658-37315C574C9CQ50319655-E1AD3B44-3C10-490B-94DF-2DCEA9CC83FBQ57151052-1B61DDD8-F4BF-4334-B8DA-FDC574A1237C
P2860
Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Population pharmacokinetic stu ...... e, severely neutropenic adults
@ast
Population pharmacokinetic stu ...... e, severely neutropenic adults
@en
type
label
Population pharmacokinetic stu ...... e, severely neutropenic adults
@ast
Population pharmacokinetic stu ...... e, severely neutropenic adults
@en
prefLabel
Population pharmacokinetic stu ...... e, severely neutropenic adults
@ast
Population pharmacokinetic stu ...... e, severely neutropenic adults
@en
P2093
P2860
P1476
Population pharmacokinetic stu ...... e, severely neutropenic adults
@en
P2093
L Guillevin
O Lortholary
O Petitjean
P Casassus
P2860
P304
P407
P577
1998-04-01T00:00:00Z